[Statement of the Austrian Society of Pneumology (ASP)].

[1]  M. Netea,et al.  Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis , 2020, Cell Host & Microbe.

[2]  Y. Bossé,et al.  SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors , 2020, The Lancet Respiratory Medicine.

[3]  W. Liang,et al.  Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China , 2020, Journal of Allergy and Clinical Immunology.

[4]  B. Cao,et al.  A Trial of Lopinavir-Ritonavir in Covid-19. Reply. , 2020, The New England journal of medicine.

[5]  F. Diekmann,et al.  Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients , 2020, American Journal of Transplantation.

[6]  D. McGonagle,et al.  Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection , 2020, Autoimmunity Reviews.

[7]  Yuling Hong,et al.  Association of a Province-Wide Intervention With Salt Intake and Hypertension in Shandong Province, China, 2011-2016. , 2020, JAMA internal medicine.

[8]  F. Rovida,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. , 2020, JAMA pediatrics.

[9]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[10]  Yan-ling Ma,et al.  Antibody Detection and Dynamic Characteristics in Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Lynnette Brammer,et al.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[12]  L. Camporota,et al.  COVID-19 pneumonia: different respiratory treatments for different phenotypes? , 2020, Intensive Care Medicine.

[13]  Kari Stefansson,et al.  Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.

[14]  T. Liang,et al.  Lung Transplantation for Elderly Patients With End-Stage COVID-19 Pneumonia , 2020, Annals of surgery.

[15]  Xihong Lin,et al.  Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. , 2020, JAMA.

[16]  J. Rello,et al.  SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria , 2020, Anaesthesia Critical Care & Pain Medicine.

[17]  Juan Du,et al.  Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study , 2020, European Respiratory Journal.

[18]  H. Kauczor,et al.  The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society , 2020, Radiology.

[19]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[20]  Ji-Man Kang,et al.  Epidemiology and clinical features of coronavirus disease 2019 in children , 2020, Clinical and experimental pediatrics.

[21]  P. Palange,et al.  Protecting healthcare workers from SARS-CoV-2 infection: practical indications , 2020, European Respiratory Review.

[22]  M. Kho,et al.  Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations , 2020, Journal of Physiotherapy.

[23]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[24]  L. D’Antiga.  Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  C. Vardavas,et al.  COVID-19 and smoking: A systematic review of the evidence , 2020, Tobacco induced diseases.

[26]  G. Wong,et al.  SARS-CoV-2 Infection in Children , 2020, The New England journal of medicine.

[27]  Huiying Liang,et al.  Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding , 2020, Nature Medicine.

[28]  T. Welte,et al.  [Recommendations for critically ill patients with COVID-19]. , 2020, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[29]  Xuehua Peng,et al.  Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults , 2020, Pediatric pulmonology.

[30]  Zhongyi Jiang,et al.  Epidemiology of COVID-19 Among Children in China , 2020, Pediatrics.

[31]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[32]  S. Trottier,et al.  Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015 , 2020, BMJ Open Respiratory Research.

[33]  Rongchang Chen,et al.  More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China , 2020, European Respiratory Journal.

[34]  Yazdan Yazdanpanah,et al.  Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists , 2020, Intensive Care Medicine.

[35]  J. Xiang,et al.  Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19) , 2020, medRxiv.

[36]  Shigui Yang,et al.  Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis , 2020, Scientific Reports.

[37]  J. González-Martín,et al.  Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.

[38]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[39]  B. Hubert,et al.  Characteristics of hospitalizations with an influenza diagnosis, France, 2012‐2013 to 2016‐2017 influenza seasons , 2020, Influenza and other respiratory viruses.

[40]  A. Wimmer,et al.  A severe influenza season in Austria and its impact on the paediatric population: mortality and hospital admission rates, november 2017 - march 2018 , 2020, BMC Public Health.

[41]  A. Zoufaly,et al.  Influenza virus infection: an approach to identify predictors for in-hospital and 90-day mortality from patients in Vienna during the season 2017/18 , 2020, Infection.

[42]  W. Lim,et al.  Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. , 2019, Critical care medicine.

[43]  Cecile Viboud,et al.  Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project , 2019, Journal of global health.

[44]  E. Giamarellos‐Bourboulis,et al.  Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis , 2019, Front. Immunol..

[45]  S. Gatermann,et al.  Analysis of acute respiratory infections due to influenza virus A, B and RSV during an influenza epidemic 2018 , 2019, Infection.

[46]  I. Bakken,et al.  Burden of medically attended influenza in Norway 2008‐2017 , 2019, Influenza and other respiratory viruses.

[47]  T. Tan,et al.  Impact of microbial Aetiology on mortality in severe community-acquired pneumonia , 2018, BMC Infectious Diseases.

[48]  A. Liapikou,et al.  Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia , 2018, PloS one.

[49]  F. Blasi,et al.  Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia , 2018, European Respiratory Journal.

[50]  Jan Kyncl,et al.  Estimates of global seasonal influenza-associated respiratory mortality: a modelling study , 2017, The Lancet.

[51]  J. Burgos,et al.  Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[52]  N. Soldevila,et al.  Factors associated with 30-day mortality in elderly inpatients with community acquired pneumonia during 2 influenza seasons , 2017, Human vaccines & immunotherapeutics.

[53]  S. Krüger,et al.  Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016 , 2016, Pneumologie.

[54]  A. Thomas,et al.  Active Bacterial Core Surveillance for Legionellosis - United States, 2011-2013. , 2015, MMWR. Morbidity and mortality weekly report.

[55]  T. Welte,et al.  Community-acquired pneumonia as medical emergency: predictors of early deterioration , 2015, Thorax.

[56]  H. Gershengorn,et al.  The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[58]  S. Jaber,et al.  Prone positioning in severe acute respiratory distress syndrome. , 2013, The New England journal of medicine.

[59]  M. Morandotti,et al.  Is influenza A(H1N1) pneumonia more severe than other community-acquired pneumonias? Results of the GiViTI survey of 155 Italian ICUs , 2011, Intensive Care Medicine.

[60]  M. Hell,et al.  Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria , 2011, Infection.

[61]  H. van Ruiten,et al.  Duchenne muscular dystrophy , 2010, BMJ.

[62]  C. C. van den Wijngaard,et al.  Surveillance of hospitalisations for 2009 pandemic influenza A(H1N1) in the Netherlands, 5 June - 31 December 2009. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[63]  T. Welte,et al.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality , 2009, Thorax.

[64]  T. Welte,et al.  Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.